Erasca | Investor Presentation Deck | 56 slides · page 39 of 56
The chart is a Kaplan-Meier survival plot. The comparison shows ERAS-801 (blue line) outperforming standard EGFR inhibitors (Erlotinib, Lapatinib, Osimertinib) and vehicle control.
Pitch deck · solution · present_solution · dense density
Slide locked Sign in to view
Slide schematic 5/5
chart 1/1 image 1/1 legend 1/1 paragraph 1/1 title 1/1
Components 5
line illustration legend paragraph headline
Tools 1
Metrics 0
∅
No metrics
No metric insight is anchored to this slide.
Frameworks 0
∅
No frameworks
No framework match is anchored to this slide.